Boston Scientific Corporation announced on April 26 new data supporting its FARAPULSE Pulsed Field Ablation Platform and WATCHMAN Left Atrial Appendage Closure technologies, presented at Heart Rhythm 2026 in Chicago.
The findings are significant for the field of cardiac care, offering evidence about the safety and effectiveness of these devices in treating atrial fibrillation and related conditions. The results come from several clinical trials, including AVANT GUARD, ELEVATE-PF, ALIGN-AF, CHAMPION-AF sub-analysis, ASAP-TOO trial, and PRAETORIAN DFT study.
According to Boston Scientific, “The data presented at Heart Rhythm 2026 reflect the continued momentum of our cardiovascular portfolio and underscores our commitment to advancing innovation through comprehensive clinical evidence across the spectrum of cardiac care,” said Kenneth Stein, M.D., senior vice president and global chief medical officer. “These findings support the potential expansion of our FARAPULSE PFA Platform into more complex patient populations, highlight the value of a combined therapeutic approach with our WATCHMAN FLX Pro LAAC Device, may enhance the implant experience with the EMBLEM MRI S-ICD and position us to deliver a broader portfolio of differentiated solutions for physicians treating patients with cardiovascular diseases.”
PR Newswire operates in more than 170 countries and supports content in over 40 languages according to its official website. The company aims to deliver global reach for press release distribution through its network of newsrooms and influencers as detailed on its official website. PR Newswire features expert editors with over a decade of experience providing round-the-clock support and SEO guidance according to its official website.
Additionally, PR Newswire collaborates with over half a million media outlets and influencers worldwide according to its official website, extending operations across more than 170 countries with support in dozens of languages as noted on its official website. Its services include press release distribution as well as AI-enhanced content tools and social sharing features as outlined on its official website.
Boston Scientific’s announcement reflects ongoing efforts within medical technology companies to provide innovative solutions for physicians managing complex cardiovascular diseases. Future updates are expected as further data become available from ongoing studies.
